{"nctId":"NCT01018394","briefTitle":"Nicotine Lozenge or Tobacco-Free Snuff for Smokeless Tobacco Reduction","startDateStruct":{"date":"2009-01"},"conditions":["Tobacco Dependence"],"count":81,"armGroups":[{"label":"nicotine lozenges","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: nicotine lozenges"]},{"label":"tobacco free snuff","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: tobacco-free snuff"]}],"interventions":[{"name":"nicotine lozenges","otherNames":[]},{"name":"tobacco-free snuff","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n1. at least 18 years of age;\n2. no intention of quitting in the next one month;\n3. report ST as their primary tobacco of use;\n4. have used ST daily for the past 12 months;\n5. have been provided with, understand, and have signed the informed consent\n6. are able to complete all study visits;\n7. are in general good health as determined by medical history.\n\nExclusion Criteria:\n\n1. currently using or have used (within the past 30 days) any other behavioral or pharmacologic tobacco treatment program;\n2. currently enrolled in another research study;\n3. describe having a medical history of: (a) unstable angina; (b) myocardial infarction within the past 6 months; (c) cardiac dysrhythmia other than medication-controlled atrial fibrillation or paroxysmal supraventricular tachycardia; or (d) medically-treated or untreated hypertension with BP ≥ 180 systolic OR ≥ 100 diastolic;\n4. have phenylketonuria (PKU) \\[nicotine lozenges contain aspartame which is metabolized to phenylalanine and not processed in individuals with PKU\\];\n5. have another member of their household already participating in this study;\n6. have other medical or psychiatric conditions that would exclude the participant in the opinion of the investigators;\n7. have a score of ≥ 15 on the Patient Health Questionnaire (PHQ-8) on the phone call pre-screen;\n8. are currently pregnant are trying to become pregnant;\n9. are currently breast-feeding and unwilling to stop during this study.","healthyVolunteers":true,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"OTHER_PRE_SPECIFIED","title":"Smokeless Tobacco Reduction Greater or Equal to 50%","description":"Percentage of participants who reduced smokeless tobacco use (cans per week) by 50% or more from baseline","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"25","spread":null},{"groupId":"OG001","value":"19","spread":null}]}]}]},{"type":"PRIMARY","title":"Tobacco Abstinence at 12 Weeks","description":"Number of participants who were biochemically confirmed abstinent from tobacco at week 12 using urinary anabasine less than 2 ng per ml.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"8","spread":null},{"groupId":"OG001","value":"5","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":0,"n":40},"commonTop":["sore throat","dizziness","insomnia"]}}}